Targeted protein degradation refers to the use of small molecules to induce the selective
degradation of proteins. In its most common form, this degradation is achieved through …

Targeted protein degradation (TPD) is an emerging modality for research and therapeutics.
Most TPD approaches harness cellular ubiquitin-dependent proteolytic pathways …

Proteolysis targeting chimera (PROTAC) degradation of pathogenic proteins by hijacking of
the ubiquitin-proteasome-system has become a promising strategy in drug design. The …

As a widely considerable target in chemical biology and pharmacological research, rat
sarcoma (RAS) gene mutations play a critical driving factor in several fatal cancers. Despite …

The ability to rapidly and selectively modulate cellular protein levels using small molecules
is essential for studying complex biological systems. Degradation tags, such as dTAG, allow …

ABSTRACT Introduction Solute carriers (SLCs) represent the largest group of membrane
transporters in the human genome. They play a central role in controlling the …

Proteolysis-targeting chimeras (PROTACs) are rapidly emerging as a potential therapeutic
strategy for cancer therapy by inducing the degradation of tumor-overexpressing oncogenic …

Proteolysis-targeting chimeras (PROTACs) describe compounds that bind to and induce
degradation of a target by simultaneously binding to a ubiquitin ligase. More generally …

Sarcomas are heterogeneous bone and soft tissue cancers representing the second most
common tumor type in children and adolescents. Histology and genetic profiling discovered …

Inducing cell ferroptosis by inactivating glutathione peroxidase 4 (GPX4) is a popular cancer
treatment strategy. However, only few GPX4 inhibitors have been developed to date …